Archive
2020, Volume 9
2019, Volume 8
2018, Volume 7
2017, Volume 6
2016, Volume 5
2015, Volume 4
2014, Volume 3
2013, Volume 2
2012, Volume 1




Volume 9, Issue 5, October 2020, Page: 91-95
Exploration of Long-term CD4 Profile in HIV Patients Under HAART at Mizan-Tepi University Teaching Hospital and Tepi General Hospital, South Western Ethiopia
Solomon Abebaw Andargie, Department of Statistics, Mizan-Tepi University, Tepi, Ethiopia
Assaye Belay Gelaw, Department of Statistics, Mizan-Tepi University, Tepi, Ethiopia
Received: Aug. 18, 2020;       Accepted: Aug. 27, 2020;       Published: Sep. 14, 2020
DOI: 10.11648/j.pamj.20200905.12      View  25      Downloads  24
Abstract
Currently, because of the wide availability and free service of HAART, HIV/AIDS related morbidity and mortality has decreased significantly. However, patients accessing antiretroviral treatment (ART) programmes in sub-Saharan Africa frequently have very advanced immunodeficiency and various reserches suggest that such patients may have diminished capacity for CD4 cell count recovery. The objective of this study was to investigate the long-term effect of highly active antiretroviral therapy on the CD4 lymphocyte count of HIV-infected Patients. Subjects from the multicenter HAART Program cohort (from Mizan-Tepi University Teaching Hospital and Tepi General Hospital), aged 18 years or older and had an ART treatment start date in between February 1, 2017 to January 31, 2019 were enrolled in the present study and followed for a maximum of 3 years. Liner mixed model with nested random effect were used to model the longitudianl CD4 count over time. The data reveal robust CD4 responses to ART that are continual over several years. Being under HAART for long period and having baseline CD4 count greater than 150 were positively associated with CD4 increment over time while starting ART at late stage (Stage 3 or 4) and being male are negatively assocted with CD4 increment over time. These study show strong and repetitive CD4 response to ART among patients remaining on therapy. Earlier HIV diagnosis and initiation of ART could significantly progress patient outcomes in the study area.
Keywords
CD4counts, HAART, ART, Liner Mixed Model, Patients
To cite this article
Solomon Abebaw Andargie, Assaye Belay Gelaw, Exploration of Long-term CD4 Profile in HIV Patients Under HAART at Mizan-Tepi University Teaching Hospital and Tepi General Hospital, South Western Ethiopia, Pure and Applied Mathematics Journal. Vol. 9, No. 5, 2020, pp. 91-95. doi: 10.11648/j.pamj.20200905.12
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
M. R. Loutfy, L. Sherr, U. Sonnenberg-schwan, S. L. Walmsley, and M. Johnson, “Review article Caring for women living with HIV : gaps in the evidence,” pp. 1–14, 2013.
[2]
M. E. Arrivé, R. Becquet, F. D. Coordinator, and V. Leroy, “HIV Care & PMTCT in Resource-Limited Settings Available on line prepared by the Bordeaux Working Group,” vol. 2, no. 8, pp. 39–50, 2006.
[3]
B. S. C. Uzochukwu, O. E. Onwujekwe, A. C. Onoka, C. Okoli, N. P. Uguru, and O. I. Chukwuogo, “Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria,” no. March, pp. 189–196, 2009, doi: 10.1093/heapol/czp006.
[4]
I. Zulu et al., “Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in Zambia Feasibility and Early Outcomes,” vol. 296, no. 7, 2006.
[5]
Y. Madec, D. Laureillard, and L. Pinoges, “Response to highly active antiretroviral therapy among severely immuno- compromised HIV-infected patients in Cambodia. Authors Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia,” 2020.
[6]
T. Opportunistic, I. Project, and O. Hiv, “CD4 Cell Count and the Risk of AIDS or Death in HIV- Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load : A Longitudinal Cohort Study from COHERE,” vol. 9, no. 3, 2012, doi: 10.1371/journal.pmed.1001194.
[7]
S. Du Mortier, S. Mukangu, C. Sagna, L. Nyffenegger, and S. A. Perone, “A decade of an HIV workplace programme in armed conflict zones ; a social responsibility response of the International Committee of the Red Cross,” J. Occup. Med. Toxicol., pp. 1–10, 2016, doi: 10.1186/s12995-016-0119-4.
[8]
W. H. O. E. Region, HIV / AIDS TREATMENT AND CARE Clinical protocols for the WHO European Region HIV / AIDS TREATMENT AND CARE Clinical protocols for the WHO European Region.
[9]
O. J. Daniel, O. Ot, O. A. Ogundahunsi, and S. Fagbenro, “Default from Anti-Retroviral Treatment Programme in Sagamu, Nigeria,” vol. 11, no. May, pp. 221–224, 2008.
[10]
S. Mcgee, J. D. Kuruc, J. L. Lennox, and D. M. Margolis, “NIH Public Access,” vol. 62, no. 5, pp. 505–508, 2014, doi: 10.1097/QAI.0b013e318285cd33. Antiretroviral.
[11]
O. Erhabor, O. A. Ejele, and C. A. Nwauche, “stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans : the Nigerian experience,” vol. 1, p. 39, 2009, doi: 10.1186/1742-4690-6-S2-P66.
[12]
J. Zhou, T. Sirisanthana, S. Kiertiburanakul, Y. A. Chen, N. Han, and P. L. Lim, “Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment : results from The TREAT Asia HIV Observational Database,” BMC Infect. Dis., vol. 10, no. 1, p. 361, 2010, doi: 10.1186/1471-2334-10-361.
[13]
A.. Bowman, F. D. and Manatunga, “A joint model for longitudinal data Profiles and associated event risks with application to a depression study,” Appl. Stat., vol. 2, no. 54, pp. 301–316, 2005.
[14]
L. Liang, K. and Zeger, Longitudinal data analysis for discrete and continuous outcomes. 1982.
Browse journals by subject